150.00
150.00
Inclusive of all taxes
You Save: 0. Discount 0%
Product is not available
FLOX-0-FLOX TAB is a fixed-dose combination of Ofloxacin (200 mg) and Ornidazole (500 mg), used to treat a wide spectrum of bacterial and protozoal infections, particularly those affecting the gastrointestinal tract, genitourinary system, and respiratory tract. This dual-action formula offers broad antimicrobial coverage, ensuring rapid symptom relief and improved patient compliance. Manufactured by BluepillExpress, a global leader in third-party pharma manufacturing, this product is offered with full regulatory and private label support for worldwide distribution.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
FLOX-0-FLOX TAB is a high-efficacy combination antimicrobial formulation consisting of Ofloxacin, a fluoroquinolone antibiotic, and Ornidazole, a nitroimidazole class antiprotozoal and antibacterial agent. This synergistic combination is ideal for mixed infections involving anaerobic bacteria and protozoa, especially in regions where such dual-pathogen infections are common.
Developed and exported by BluepillExpress, this formulation is manufactured in WHO-GMP certified facilities under strict international quality controls. It is widely used in both hospital and community settings for treating gastrointestinal infections, dysentery, bacterial vaginosis, post-operative infections, and gynecological infections.
Therapeutic Indications
Acute diarrheal conditions with suspected bacterial and protozoal causes
Amoebiasis and Giardiasis
Bacterial vaginosis and mixed vaginal infections
Pelvic inflammatory disease (PID)
Urinary tract infections (UTIs)
Post-surgical infections of the abdomen and pelvis
Dental infections and periodontal infections
Respiratory tract infections where anaerobic coverage is needed
Mechanism of Action
Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to the prevention of DNA replication and bacterial death.
Ornidazole enters anaerobic cells and protozoa, where it undergoes reduction to active metabolites that disrupt DNA synthesis, causing cell death.
This combination ensures a broad-spectrum action covering both aerobic and anaerobic bacteria as well as protozoa, reducing the need for multiple drugs.
